课题基金 / 基金详情

Development of Mice with Conditional ICAM-1 Deletion

Development of Mice with Conditional ICAM-1 Deletion
条件性 ICAM-1 缺失小鼠的发育
批准号:
10259661
负责人:
James Jason Collier
金额:
$7.89万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-09-09 至 2023-05-31

项目摘要

项目成果

James Jason Collier的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The generation of research resources designed to uncover novel mechanisms of islet beta-cell interaction with the immune system are vitally important for progress in understanding autoimmune disease onset and progression, enhancing drug development strategies, and other curative endeavors. Intracellular adhesion molecule-1 (ICAM-1) is a critical component in the development of type 1 diabetes (T1D) but the tissue-specific contributions of this protein have not been examined due to lack of available and appropriate model systems. Herein, we outline a strategy to make transgenic mice with conditional deletion of ICAM-1 on both the C57BL/6 and non-obese diabetic (NOD) backgrounds. This R03 project will generate two novel and important mouse lines with which to probe basic mechanisms underlying autoimmune onset and progression of T1D, and importantly, provide insights into how immune cells destroy islet beta cells. These new mouse lines will make it possible to test innovative hypotheses only conceivable with tissue-specific gene deletions, providing important mechanistic insights into events regulating autoimmunity, pancreatic islet inflammation, tissue graft rejection, vascularization events, and T1D onset. We anticipate broad applicability to studies of other diseases with autoimmune and auto-inflammatory components and for general studies on the biology of the ICAM-1 protein.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SGK1 is a regulator of islet beta cell mass and secretory function
SGK1 is a regulator of islet beta cell mass and secretory function
SGK1 is a regulator of islet beta cell mass and secretory function
A Unique Receptor Agonist Approach for Type 1 Diabetes Prevention
国内基金
海外基金
Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis